Cardiac Pathways gets go-ahead for ablation catheters:
This article was originally published in Clinica
Cardiac Pathways has received pre-market approval (PMA) for its Chillirpm cooled ablation catheters, including the company's Real-time Position Management navigation technology. The device includes a bi-directional steering capability and integrates the company's ultrasound transducer technology for dynamic real-time catheter navigation and visualisation. The PMA provides the additional approval necessary to use the RPM technology for therapy, the Sunnyvale, California-based company said.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.